Publications

Krafft Temperature of Surfactants in Vehicles for Roflumilast and Pimecrolimus Cream and Effects on Skin Tolerability

Once-Daily Roflumilast Foam 0.3% for Severity and Burden of Itch in Patients with Scalp and Body Psoriasis in a Randomized, Double-Blind, Vehicle-Controlled Phase 2b Study

A Randomized, Double-Blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients with Moderate to Severe Seborrheic Dermatitis

Correlation of Itch Response to Roflumilast Cream with Disease Severity and Patient-Reported Outcomes in Patients with Chronic Plaque Psoriasis

Effect of Roflumilast Cream on Chronic Plaque Psoriasis in Patients with Steroid-Sensitive Area Involvement

Once-Daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-Blind, Vehicle-Controlled Phase 2b Study

The PASI-HD for Precision in Measuring Disease Severity in Subjects with Mild to Moderate Plaque Psoriasis Treated with Roflumilast Cream, a Phosphodiesterase-4 Inhibitor

Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients with Psoriasis (DERMIS-1 and DERMIS-2)

Roflumilast Cream 0.3% for the Severity and Impact of Itch in Patients with Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies